Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.18
DVA's Cash to Debt is ranked lower than
61% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. DVA: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
DVA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.11 Max: 5.2
Current: 0.18
0
5.2
Equity to Asset 0.25
DVA's Equity to Asset is ranked lower than
79% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. DVA: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
DVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.25 Max: 0.64
Current: 0.25
0.03
0.64
Interest Coverage 3.51
DVA's Interest Coverage is ranked lower than
72% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 7.88 vs. DVA: 3.51 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: N/A
Current: 3.51
F-Score: 6
Z-Score: 2.05
M-Score: -2.82
WACC vs ROIC
6.07%
5.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.09
DVA's Operating margin (%) is ranked higher than
60% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 6.90 vs. DVA: 10.09 )
Ranked among companies with meaningful Operating margin (%) only.
DVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 10.09
8.49
17.15
Net-margin (%) 2.51
DVA's Net-margin (%) is ranked lower than
64% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. DVA: 2.51 )
Ranked among companies with meaningful Net-margin (%) only.
DVA' s Net-margin (%) Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 7.25
Current: 2.51
1.96
7.25
ROE (%) 7.37
DVA's ROE (%) is ranked lower than
58% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. DVA: 7.37 )
Ranked among companies with meaningful ROE (%) only.
DVA' s ROE (%) Range Over the Past 10 Years
Min: 5.37  Med: 20.55 Max: 27.64
Current: 7.37
5.37
27.64
ROA (%) 1.93
DVA's ROA (%) is ranked lower than
67% of the 241 Companies
in the Global Medical Care industry.

( Industry Median: 4.28 vs. DVA: 1.93 )
Ranked among companies with meaningful ROA (%) only.
DVA' s ROA (%) Range Over the Past 10 Years
Min: 1.49  Med: 4.86 Max: 5.69
Current: 1.93
1.49
5.69
ROC (Joel Greenblatt) (%) 45.36
DVA's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 19.96 vs. DVA: 45.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 38.04  Med: 56.94 Max: 68.47
Current: 45.36
38.04
68.47
Revenue Growth (3Y)(%) 15.10
DVA's Revenue Growth (3Y)(%) is ranked higher than
76% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. DVA: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 15.1 Max: 39.8
Current: 15.1
4.8
39.8
EBITDA Growth (3Y)(%) -0.60
DVA's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 142 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. DVA: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.3  Med: 15 Max: 98.2
Current: -0.6
-25.3
98.2
EPS Growth (3Y)(%) -23.00
DVA's EPS Growth (3Y)(%) is ranked lower than
90% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. DVA: -23.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: -23
-29
125.5
» DVA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DVA Guru Trades in Q3 2015

Joel Greenblatt 48,381 sh (New)
Arnold Van Den Berg 285,918 sh (+85.75%)
Steve Mandel 7,918,998 sh (+45.15%)
Mario Gabelli 41,763 sh (unchged)
Warren Buffett 38,565,570 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Manning & Napier Advisors, Inc 1,405,605 sh (-1.13%)
Alan Fournier 1,999,797 sh (-7.35%)
Jim Simons 408,600 sh (-43.77%)
Andreas Halvorsen 2,735,075 sh (-44.95%)
» More
Q4 2015

DVA Guru Trades in Q4 2015

Paul Tudor Jones 20,656 sh (New)
Ray Dalio 31,945 sh (New)
Joel Greenblatt 302,502 sh (+525.25%)
Jim Simons 924,100 sh (+126.16%)
Manning & Napier Advisors, Inc 1,887,295 sh (+34.27%)
Warren Buffett 38,565,570 sh (unchged)
Steve Mandel Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 39,963 sh (-4.31%)
Arnold Van Den Berg 268,133 sh (-6.22%)
Alan Fournier 1,286,097 sh (-35.69%)
» More
Q1 2016

DVA Guru Trades in Q1 2016

Andreas Halvorsen 1,744,519 sh (New)
Joel Greenblatt 513,100 sh (+69.62%)
Arnold Van Den Berg 328,908 sh (+22.67%)
Jim Simons 1,091,500 sh (+18.11%)
Mario Gabelli 41,563 sh (+4.00%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
Warren Buffett 38,565,570 sh (unchged)
Alan Fournier Sold Out
Paul Tudor Jones Sold Out
Ray Dalio 6,600 sh (-79.34%)
» More
Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:OTCPK:IHHHF, NYSE:UHS, OTCPK:BDULF, OTCPK:MCFFY, OTCPK:SKHCY, NYSE:MD, NAS:WOOF, OTCPK:CAKFY, NAS:ACHC, NYSE:HLS, NAS:AMSG, OTCPK:HHCSY, OTCPK:LTGHY, NAS:LPNT, NYSE:THC, NYSE:CHE, NYSE:AHS, NAS:SCAI, NAS:AMED, NYSE:SEM » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services mainly in dialysis centers and in contracted hospitals across the United States. It also operates other ancillary services and strategic initiatives.

DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.

Top Ranked Articles about DaVita HealthCare Partners Inc

Arnold Van Den Berg Sells Coca-Cola, DaVita Largest trades by the investor in the second quarter
Arnold Van Den Berg (Trades, Portfolio) is a value investor and considers himself a student of Benjamin Graham. His investment research seeks to determine the appraised value of a company, often referred to as intrinsic value. Read more...
Low P/S Ratios for DaVita, ConAgra Foods Gurus have been snapping up these stocks
According to GuruFocus' All-in-One Screener, the following are companies with market caps above $5 billion that are trading with low P/S ratios. Read more...
Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...
Steve Mandel Sells Health Care Stakes Guru sells holdings in Allergan and DaVita HealthCare Partners
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, sold out two health care stakes in the fourth quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.90
DVA's P/E(ttm) is ranked lower than
71% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 25.32 vs. DVA: 37.90 )
Ranked among companies with meaningful P/E(ttm) only.
DVA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.6  Med: 19.68 Max: 58.72
Current: 37.9
11.6
58.72
Forward P/E 16.64
DVA's Forward P/E is ranked higher than
63% of the 70 Companies
in the Global Medical Care industry.

( Industry Median: 18.38 vs. DVA: 16.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 37.90
DVA's PE(NRI) is ranked lower than
70% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 25.51 vs. DVA: 37.90 )
Ranked among companies with meaningful PE(NRI) only.
DVA' s PE(NRI) Range Over the Past 10 Years
Min: 11.57  Med: 19.53 Max: 58.72
Current: 37.9
11.57
58.72
Price/Owner Earnings (ttm) 45.22
DVA's Price/Owner Earnings (ttm) is ranked lower than
71% of the 91 Companies
in the Global Medical Care industry.

( Industry Median: 25.12 vs. DVA: 45.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.66  Med: 16.77 Max: 674.95
Current: 45.22
9.66
674.95
P/B 2.81
DVA's P/B is ranked lower than
55% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 2.59 vs. DVA: 2.81 )
Ranked among companies with meaningful P/B only.
DVA' s P/B Range Over the Past 10 Years
Min: 2.36  Med: 3.29 Max: 7.09
Current: 2.81
2.36
7.09
P/S 0.95
DVA's P/S is ranked higher than
68% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. DVA: 0.95 )
Ranked among companies with meaningful P/S only.
DVA' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.18 Max: 2.34
Current: 0.95
0.77
2.34
PFCF 10.64
DVA's PFCF is ranked higher than
81% of the 112 Companies
in the Global Medical Care industry.

( Industry Median: 23.05 vs. DVA: 10.64 )
Ranked among companies with meaningful PFCF only.
DVA' s PFCF Range Over the Past 10 Years
Min: 7.52  Med: 17.03 Max: 42.52
Current: 10.64
7.52
42.52
POCF 6.66
DVA's POCF is ranked higher than
82% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 13.81 vs. DVA: 6.66 )
Ranked among companies with meaningful POCF only.
DVA' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 9.4 Max: 17.87
Current: 6.66
5.22
17.87
EV-to-EBIT 14.35
DVA's EV-to-EBIT is ranked higher than
67% of the 185 Companies
in the Global Medical Care industry.

( Industry Median: 19.90 vs. DVA: 14.35 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.5 Max: 21.5
Current: 14.35
8.5
21.5
EV-to-EBITDA 9.80
DVA's EV-to-EBITDA is ranked higher than
76% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 14.18 vs. DVA: 9.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.8 Max: 17.1
Current: 9.8
6.8
17.1
PEG 3.99
DVA's PEG is ranked lower than
71% of the 75 Companies
in the Global Medical Care industry.

( Industry Median: 2.55 vs. DVA: 3.99 )
Ranked among companies with meaningful PEG only.
DVA' s PEG Range Over the Past 10 Years
Min: 0.41  Med: 1.42 Max: 5.58
Current: 3.99
0.41
5.58
Shiller P/E 27.61
DVA's Shiller P/E is ranked higher than
53% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 27.54 vs. DVA: 27.61 )
Ranked among companies with meaningful Shiller P/E only.
DVA' s Shiller P/E Range Over the Past 10 Years
Min: 19.65  Med: 30.46 Max: 58.5
Current: 27.61
19.65
58.5
Current Ratio 1.70
DVA's Current Ratio is ranked higher than
64% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. DVA: 1.70 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.86 Max: 5.97
Current: 1.7
0.39
5.97
Quick Ratio 1.62
DVA's Quick Ratio is ranked higher than
67% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.23 vs. DVA: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.8 Max: 5.97
Current: 1.62
0.37
5.97
Days Inventory 6.45
DVA's Days Inventory is ranked higher than
82% of the 173 Companies
in the Global Medical Care industry.

( Industry Median: 17.96 vs. DVA: 6.45 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.45
3.72
8.61
Days Sales Outstanding 47.68
DVA's Days Sales Outstanding is ranked lower than
55% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 43.71 vs. DVA: 47.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 63.93 Max: 69.73
Current: 47.68
43.53
69.73
Days Payable 17.93
DVA's Days Payable is ranked lower than
76% of the 148 Companies
in the Global Medical Care industry.

( Industry Median: 38.51 vs. DVA: 17.93 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 21.11 Max: 27.1
Current: 17.93
14.92
27.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 125 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. DVA: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -0.8 Max: 9.3
Current: 0.2
-22.6
9.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.85
DVA's Price/Projected FCF is ranked higher than
86% of the 93 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. DVA: 0.85 )
Ranked among companies with meaningful Price/Projected FCF only.
DVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 1.15 Max: 6.25
Current: 0.85
0.83
6.25
Price/DCF (Earnings Based) 3.14
DVA's Price/DCF (Earnings Based) is ranked lower than
97% of the 29 Companies
in the Global Medical Care industry.

( Industry Median: 1.58 vs. DVA: 3.14 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.81
DVA's Price/Median PS Value is ranked higher than
78% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 1.09 vs. DVA: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
DVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.04 Max: 4.97
Current: 0.81
0.15
4.97
Price/Peter Lynch Fair Value 4.60
DVA's Price/Peter Lynch Fair Value is ranked lower than
84% of the 44 Companies
in the Global Medical Care industry.

( Industry Median: 2.44 vs. DVA: 4.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.26 Max: 8.16
Current: 4.6
0.39
8.16
Earnings Yield (Greenblatt) (%) 6.94
DVA's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 228 Companies
in the Global Medical Care industry.

( Industry Median: 4.20 vs. DVA: 6.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8 Max: 11.8
Current: 6.94
4.7
11.8
Forward Rate of Return (Yacktman) (%) 14.65
DVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
67% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 10.82 vs. DVA: 14.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.3  Med: 20.7 Max: 34.6
Current: 14.65
12.3
34.6

More Statistics

Revenue (TTM) (Mil) $14,358
EPS (TTM) $ 1.70
Beta0.88
Short Percentage of Float1.60%
52-Week Range $61.36 - 78.94
Shares Outstanding (Mil)206.90

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 14,661 15,616
EPS ($) 3.82 4.28
EPS w/o NRI ($) 3.82 4.28
EPS Growth Rate
(3Y to 5Y Estimate)
13.61%
Dividends Per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Starting With GAAP Jun 11 2015 
Berkshire Hathaway: Business Value Exceeds Market Value May 26 2015 

More From Other Websites
DaVita Celebrates Recent Awards Aug 25 2016
DaVita affiliate proposes Lockport's first dialysis clinic Aug 25 2016
Modern Healthcare magazine details Colorado's top health-care power brokers Aug 24 2016
ETF’s with exposure to DaVita HealthCare Partners, Inc. : August 24, 2016 Aug 24 2016
DaVita Kidney Care Welcomes Dr. Jeff Giullian to Physician Leadership Team Aug 23 2016
Sunday links: identifying talents Aug 21 2016
Fallout from Obamacare probe as shares of dialysis firms drop Aug 19 2016
Why Pure Storage, Davita, Ensco and 2 Other Stocks are Falling Hard Today Aug 19 2016
Good, bad, ugly: FL, XLE & DVA Aug 19 2016
DaVita (DVA) Stock Slides as CMS Investigates Inappropriate Patient Steering Aug 19 2016
NVIDIA, DaVita HealthCare Partners, Cisco Systems, L Brands and NetApp highlighted as Zacks Bull and... Aug 18 2016
Bear of the Day: DaVita HealthCare Partners (DVA) Aug 18 2016
DaVita (DVA) Continues to Underperform: Time to Offload it? Aug 17 2016
DAVITA HEALTHCARE PARTNERS INC. Financials Aug 13 2016
Mega-pharmacy with 550 jobs opening in Chandler Aug 12 2016
ETF’s with exposure to DaVita HealthCare Partners, Inc. : August 11, 2016 Aug 11 2016
DaVita HealthCare Partners, Inc. :DVA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10,... Aug 10 2016
DaVita HealthCare's Chart Is Looking Poorly Aug 09 2016
DaVita HealthCare's Chart Is Doing Poorly Aug 09 2016
A Closer Look at Five Stocks in Spotlight Following Financial Reports Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)